12:00 AM
 | 
May 21, 2007
 |  BioCentury  |  Regulation

Guidance comparisons

Guidance comparisons

Guidance comparisons
CMS's proposed National Coverage Decision for ESAs to treat anemia in cancer patients is more restrictive than practice guidelines from the American Society of Hematology (ASH)/Amercian Society for Clinical Oncology (ASCO), the European Organization for Research and Treatment of Cancer (EORTC) and the National Comprehensive Cancer Network (NCCN). Critical differences include initial hemoglobin (Hb) level, treatment duration, and off-label uses. In the U.K., the guidance is even narrower. In a final appraisal issued in March 2006, the National Institute...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >